Does Cosentyx Affect Vaccine Response After Injection?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can blunt antibody production and immune memory after vaccination, even post-injection. Clinical studies show reduced seroconversion rates for certain vaccines in patients on Cosentyx.
- Influenza vaccine: Seroprotection drops to 40-60% vs. 80-90% in healthy adults.[1]
- Pneumococcal vaccine: Lower antibody titers, with protection in only ~50% of cases.[2]
- COVID-19 vaccines: Diminished neutralizing antibodies, especially boosters, per observational data.[3]
Effects last during treatment (typically 4-week dosing intervals), with partial recovery after discontinuation, but full normalization may take months.
Which Vaccines Are Most Impacted?
Live vaccines (e.g., MMR, varicella, oral polio) are contraindicated during Cosentyx use due to infection risk.[4] Inactivated or mRNA vaccines (flu, COVID-19, HPV, hepatitis) show reduced but measurable response—often 20-50% lower efficacy. Tdap and shingles vaccines have mixed data; anti-pertussis antibodies may be preserved better than others.[1][2]
| Vaccine Type | Response on Cosentyx | Recommendation |
|--------------|-----------------------|----------------|
| Live (e.g., shingles Zostavax) | Avoid entirely | Delay until off-drug |
| Inactivated (e.g., flu, pneumococcal) | Reduced (40-70% efficacy) | Vaccinate but monitor titers |
| mRNA (e.g., COVID-19) | Moderate reduction; boosters help | Proceed, consider extra doses |
How Long Does the Effect Last?
Immune suppression peaks 1-2 weeks post-injection and persists through the 4-week cycle. Vaccine response improves if given mid-cycle or off-drug for 3+ months. A 2023 study found antibody levels recover to near-baseline 6 months after stopping Cosentyx.[3]
What Do Guidelines Say?
- FDA label: "Avoid live vaccines; use caution with non-live."[4]
- ACR guidelines: Vaccinate before starting biologics; re-vaccinate high-risk patients on therapy.[5]
- EULAR: Monitor titers for pneumococcal/flu in immunosuppressed; consider boosters.[6]
Patient Experiences and Risks
Real-world reports note higher breakthrough infections post-vaccination (e.g., flu despite shot). Risk of severe COVID-19 remains if response is poor. Test antibody levels pre/post-vaccination for high-risk cases like elderly or immunocompromised.[3]
Strategies to Optimize Response
- Time vaccines 4-8 weeks before Cosentyx start.
- Use adjuvanted vaccines (e.g., Fluad for flu).
- Boosters: Extra COVID-19 doses restore protection in ~70%.[3]
- Switch biologics? TNF inhibitors (e.g., Humira) preserve response better than IL-17/IL-23 drugs.[7]
Sources
[1] JAMA Dermatol 2018
[2] Ann Rheum Dis 2020
[3] Rheumatology 2023
[4] Cosentyx FDA Label 2023
[5] ACR Guidelines 2021
[6] EULAR 2021
[7] Lancet Rheumatol 2021